U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies, December 2015

In the United States (U.S.) benign prostatic hyperplasia (BPH) and prostatitis currently affect over 10 million men, lowering quality of life with painful symptoms that can be difficult to manage.  The U.S. market for minimally invasive products for the treatment of BPH and prostatitis includes pharmaceutical and minimally invasive surgical systems aimed at treating the symptoms of BPH/prostatitis.  New therapies in development offer the potential to change the way that symptomatic BPH and prostatitis patients live their lives, improving quality of life through adequate management of symptoms.  Pharmaceuticals used in the treatment of symptoms play an integral role in the treatment of urological conditions, and often represent the first-line of treatment in symptomatic patients.  Medical management will continue to have a major impact on the treatment of patients during the forecast period covered by this report, representing the primary competitive therapy to the minimally invasive therapeutic products segment.  The overall market for minimally invasive surgical systems used in the treatment of BPH and prostatitis was valued at $168.8 million in 2014.  Over the forecast period covered by this report, total sales are expected to increase at a compound annual growth rate of 3.2%, reaching an estimated $197.2 million by the year 2019.  Minimally invasive therapies for the treatment of symptomatic BPH account for the overwhelming majority of total sales for this market.

This report will cover:

• minimally invasive and pharmaceutical products for the treatment of enlarged prostates due to BPH or prostatitis;
• procedure and market forecasts for the years 2014 to 2019;
• key factors influencing the growth of individual product markets;
• estimated market shares and sales among major U.S. suppliers;
• major supplier product portfolio analysis in individual product markets; and,
• emerging technology therapies that could potentially change the treatment paradigm of BPH and prostatitis.